- Home
- ARDX vs TRVI Comparison
ARDX vs TRVI Comparison
Compare ARDX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- TRVI
- Stock Information
- Founded
- ARDX 2007
- TRVI 2011
- Country
- ARDX United States
- TRVI United States
- Employees
- ARDX N/A
- TRVI N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ARDX Health Care
- TRVI Health Care
- Exchange
- ARDX Nasdaq
- TRVI Nasdaq
- Market Cap
- ARDX 885.2M
- TRVI 725.7M
- IPO Year
- ARDX 2014
- TRVI 2019
- Fundamental
- Price
- ARDX $3.93
- TRVI $5.70
- Analyst Decision
- ARDX Strong Buy
- TRVI Strong Buy
- Analyst Count
- ARDX 9
- TRVI 9
- Target Price
- ARDX $10.17
- TRVI $19.94
- AVG Volume (30 Days)
- ARDX 4.6M
- TRVI 2.2M
- Earning Date
- ARDX 07-31-2025
- TRVI 08-07-2025
- Dividend Yield
- ARDX N/A
- TRVI N/A
- EPS Growth
- ARDX N/A
- TRVI N/A
- EPS
- ARDX N/A
- TRVI N/A
- Revenue
- ARDX $361,706,000.00
- TRVI N/A
- Revenue This Year
- ARDX $12.01
- TRVI N/A
- Revenue Next Year
- ARDX $34.66
- TRVI N/A
- P/E Ratio
- ARDX N/A
- TRVI N/A
- Revenue Growth
- ARDX 127.33
- TRVI N/A
- 52 Week Low
- ARDX $3.21
- TRVI $2.36
- 52 Week High
- ARDX $8.06
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- ARDX 57.99
- TRVI 41.92
- Support Level
- ARDX $3.49
- TRVI $5.41
- Resistance Level
- ARDX $3.72
- TRVI $5.96
- Average True Range (ATR)
- ARDX 0.16
- TRVI 0.29
- MACD
- ARDX 0.06
- TRVI -0.06
- Stochastic Oscillator
- ARDX 98.21
- TRVI 24.79
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.